As of November 14, 2026, Definium Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 29, 2026 (Form 8-K, January 29, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Definium Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Definium Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-29. Every row below is cited to the filing it comes from, and this page adds each new change as Definium Therapeutics, Inc. files it.
Also on the record for Definium Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Capital World Investors | 6.1% of the class | 5%+ stakes | Source |
| November 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 1.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by DRIEHAUS CAPITAL MANAGEMENT LLC | 5.36% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 3.01% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Avoro Capital Advisors LLC | 5.08% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by DRIEHAUS CAPITAL MANAGEMENT LLC | 6.64% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 7.2% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 5.54% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.87% of the class | 5%+ stakes | Source |
| May 5, 2025 | Form D, private offering | $7M sold | Form D page | Source |
Selling to them or working with them? See who runs Definium Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Definium Therapeutics, Inc. and the records around it.
Definium Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Cue Biopharma, Inc. (Aug 2026), Frequency Electronics, Inc. (Aug 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 41 other companies: Mentari Therapeutics, Inc. (Nov 2026), Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026)
Watch Definium Therapeutics, Inc.
Get an email when Definium Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Definium Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Definium Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Definium Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-29 | Reported | not named in the filing | 8-K, 2026-01-29 |
New leaders reset buying decisions — get the Full Report on Definium Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Definium Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Definium Therapeutics, Inc.Every change, in the filing's words
Reported
Mr. Adsett was not named to any committees in connection with his appointment.
- On January 28, 2026, the Board of Directors (the "Board") of Definium Therapeutics, Inc. (the "Company"), upon recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from six (6) to seven (7) directors and appointed Roger Adsett to fill the vacancy on the Board, effective January 29, 2026, with a term expiring at the Company's annual general meeting of shareholders to be held in 2026, or until his s uccessor is duly elected or appointed, or until his earlier death, resignation or removal.
- Mr. Adsett will be compensated in accordance with the Company's non-employee director compensation policy, as amended (the "Policy").
- Pursuant to the Policy, Mr. Adsett will be entitled to receive $40,000 per year for service as a member of the Board, paid quarterly in arrears on a pro-rata basis.
- In addition, pursuant to the Policy and in connection with his appointment to the Board as a non-employee director, Mr. Adsett was granted an option to purchase 50,000 common shares of the Company (the "Initial Option Grant"), which will vest one-third on the first anniversary of the grant date, with the remaining portion vesting in equal monthly installments thereafter, subject to Mr. Adsett's continued service on the Board through each applicable vesting date.
Tools for this story
Each opens in a new tab, filled in for Definium Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
